Pre-clinical Studies

Nash’s NASH NP-160 shows repeated positive results in second pre-clinical study

Nash Pharmaceuticals, a subsidiary of Breathtec Biomedical, has announced that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories.

Redx expects to start first-in-man studies with RXC006 during 2020

UK-based Redx Pharma said it expects to start first-in-man studies with RXC006 during 2020 as the first pre-clinical data of the drug candidate has suggested that the compound has great potential as a fibrosis treatment.

Cyxone MS drug T20K succeeds in preclinical program

Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies.

Scientists engineer DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus

Scientists at The Wistar Institute and collaborators have engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models.

Inovio develops DNA-encoded monoclonal antibody checkpoint inhibitor

Inovio Pharmaceuticals said that it has completed animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4.

Scientists discover potential druggable target for lung cancer treatment

Scientists in the UK claim to have identified a crucial molecular player in a subtype of lung cancer that could pave way for a new approach towards treating the condition.

Study finds new drug treatment could reduce liver transplants

Scientists in the UK believe that patients with sudden liver failure could benefit from a new treatment in the future that could cut down the need for transplants by preventing a process called senescence with certain anti-cancer therapy drugs.

Oxford BioMedica forms three-way partnership for cystic fibrosis treatment

Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations for the development of a long-term therapy to treat patients with cystic fibrosis.

Kalytera scraps pre-clinical programs in bone disease

Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.